Shukra Pharmaceuticals profit and loss

Latest FY24

Revenue: ₹74.6cr+26.8% on FY23
EBITDA: ₹19.4cr+261.8% on FY23
Net profit: ₹18.5cr+320.7% on FY23
EPS: ₹23.00−12.2% on FY23

₹ crore except per share

Tap a line for its trend	FY24Mar 2024	FY23Mar 2023

Expenses
	74.6	58.8
	2.8	1.2
	77.4	60.0
	0.2	0.2
	0.7	−0.3
	5.6	4.9
	0.3	0.3
	2.1	1.8
	5.0	3.3
	19.4	5.4
	17.4	3.5
Profit
	19.9	4.4
	19.9	4.4
	1.4	0.2
	−0.0	0.0
	1.3	0.0
	18.5	4.4
	18.5	4.4
Per share
	₹23.00	₹26.21
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	73.7	59.0
	98.8%	100.3%
Adjusted (ex-exceptional items) — derived
	19.9	4.4
	18.5	4.4
	₹23.00	₹26.21

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SHUKRAPHAR₹71.92

Shukra Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SGRL SUNLOCMcap ₹58 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024
Revenue from Operations	58.8	74.6
Other Income	1.2	2.8
Total Income	60.0	77.4
Expenses
+ Purchases of Stock-in-Trade	0.2	0.2
+ Changes in Inventories	-0.3	0.7
+ Employee Benefit Expense	4.9	5.6
+ Finance Costs	0.3	0.3
+ Depreciation & Amortisation	1.8	2.1
+ Other Expenses	3.3	5.0
EBITDA	5.4	19.4
EBIT	3.5	17.4
Profit
PBT before Exceptional Items	4.4	19.9
Pretax Income	4.4	19.9
+ Current Tax	0.2	1.4
+ Deferred Tax	0.0	-0.0
Tax Expense	0.0	1.3
Net Income	4.4	18.5
Total Comprehensive Income	4.4	18.5
Per Share
Basic EPS	26.21	23.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	59.0	73.7
Gross Margin %	100.29	98.82
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	4.4	19.9
Net Income Adj (tax-effected)	4.4	18.5
EPS Adj	26.21	23.00

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.